Sorry for not picking this up before my last post. It is from the Nov 08 company press release:

"The recent change in the world's economy poses a challenge to high technology companies in the process of commercializing their technologies. Our response to that challenge is to focus all of our resources in generating revenue as soon as possible, from signing a third semi-exclusive licensing agreement to commercializing manual tests. It is difficult to tell where the first revenues will come from; our licensees or direct sales, but working on all fronts in parallel maximizes our opportunities and expedites the process. To the best of our knowledge, no other technology can match this product. The profit margin should be considerable."

This really doesn't explain much about when revenue could be flowing. For instance, it could mean that either revenue from China is going to be slower coming than the big contracts or the big licenses will pay off sooner than expected. Though I doubt the latter, because I expect there would be the usual (for any company in this industry) leaks or inside activity that would boost trading ahead of an announcement.

Nonetheless, I am hoping things could happen quicker with oncology tests than with oncology treatments. Waiting out clinical trials for treatment -- despite some fast track situations -- are usually like watching an anaconda swallow a pig. Any experts out there know if it is different for tests? I can only guess it would be quicker for tests since there is no direct danger from their use; just the indirect risk of erroneous decisions based on the result.

At any rate, the Nov 08 release still doesn't tell me whether moving into China now was part of the master plan before the capital meltdown. Any other info out there on that topic?